SAIPARENT

Sai Parenterals completed the acquisition of a 60% equity stake in Prathyak Laboratories (renamed Sai Prathyak Laboratories) for Rs. 15 crore, funded from IPO proceeds. - The acquisition replaces a planned greenfield R&D facility, providing an operational research centre at Genome Valley, Hyderabad. - Prathyak brings 28 research scientists and a pipeline of 150 SKUs across 86 molecules in complex injectables and oncology. - The company holds a Right of First Refusal (ROFR) to acquire the remaining 40% stake at the same valuation from internal accruals.

Concall Schedule Concall Date: 14th October 2026 (Wednesday) Concall Time: 11:00 am onwards

- Sai Parenterals Limited accepted the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer effective 30th September 2026 due to personal reasons. - Appointed Mr. Ashwani Singh Bisht as the new Company Secretary & Compliance Officer w.e.f. 30th September 2026. - Appointed Mr. Arvind Gannimitta as the Chief Operating Officer w.e.f. 30th September 2026.

- Resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer effective September 30, 2026. - Appointment of Mr. Ashwani Singh Bisht as the new Company Secretary & Compliance Officer w.e.f. September 30, 2026. - Appointment of Mr. Arvind Gannimitta as the Chief Operating Officer w.e.f. September 30, 2026.

- The 25th Annual General Meeting (AGM) of Sai Parenterals Limited was held on September 10, 2026, via video conferencing. - All 12 proposed resolutions were passed. - Key resolutions included adoption of FY26 financial statements, re-appointment of Anil Kumar Karusala as Managing Director and Vijitha Gorrepati as Whole-Time Director. - Other approvals covered variation in IPO proceeds utilization, ESOP schemes, related party transactions, and ratification of cost auditor remuneration.